We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients at first relapse.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Larocca, Alessandra;
2021-01-01
Abstract
We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients at first relapse.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
European J of Haematology - 2021.pdf
Accesso aperto
Descrizione: [PUBLISHED Vsn.] Richardson et al. Eur J Haematol. 2022 Jan;108(1):73-83. doi: 10.1111/ejh.13706. © 2021 The Authors. Available at: https://onlinelibrary.wiley.com/doi/10.1111/ejh.13706 --- https://doi.org/10.1111/ejh.13706
Tipo di file:
PDF EDITORIALE
Dimensione
389.25 kB
Formato
Adobe PDF
|
389.25 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
